AC
BMRN icon

AXQ Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

AXQ Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,036
Closed -$1.55M – 1014
2025
Q4 		$1.55M Buy
+26,036
New +$1.42M 0.35% 69
2025
Q3 		– Sell
-12,175
Closed -$669K – 597
2025
Q2 		$669K Buy
+12,175
New +$717K 0.22% 145
2024
Q4 		– Sell
-23,022
Closed -$1.62M – 444
2024
Q3 		$1.62M Buy
23,022
+2,323
+11% +$194K 0.49% 37
2024
Q2 		$1.7M Buy
20,699
+5,399
+35% +$449K 0.4% 73
2024
Q1 		$1.34M Buy
15,300
+11,100
+264% +$994K 0.32% 91
2023
Q4 		$405K Sell
4,200
-200
-5% -$17.7K 0.11% 310
2023
Q3 		$389K Sell
4,400
-1,100
-20% -$97.9K 0.14% 258
2023
Q2 		$477K Buy
+5,500
New +$518K 0.59% 41

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AXQ Capital's BMRN Position: Q1 2026 in Review

AXQ Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 26,036 shares — an estimated $1.55M sold.

AXQ Capital first reported a position in BMRN in Q2 2023 and held it in 8 quarters. The position peaked at $1.7M in Q2 2024. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • AXQ Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AXQ Capital sold 26,036 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.55M.
  • AXQ Capital first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • AXQ Capital's BioMarin Pharmaceuticals position peaked at $1.7M in Q2 2024.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.